Telix Pharmaceuticals Ltd — Board/Management Information 2018

Feb 28, 2018

==> picture [143 x 79] intentionally omitted <==

Odile Jaume to Lead Telix’s European Operations

Melbourne (Australia) and Brussels (Belgium) – 1[st] of March, 2018 . Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today announced the appointment of Ms. Odile Jaume as President and Chief Operating Officer (COO) of Telix’s European operations.

Telix has established several EU/UK entities as part of delivering the Company’s intellectual property management, clinical operations and manufacturing activities in Europe. Telix is currently executing a significant portfolio of clinical research activities in Europe to support key clinical trials for TLX-250 and TLX-101, as well as indication expansion for Telix’s pipeline.

Telix Co-Founder and CEO Dr. Christian Behrenbruch stated, “It’s my great pleasure to welcome Odile to the team, and for her to take charge of our European operations. Europe has a highly sophisticated nuclear medicine ecosystem that Odile knows very well, and we are pleased to have the benefit of her managerial and business development acumen.”

Based in Brussels, Ms. Jaume’s responsibilities include managing Telix’s collaborative and clinical relationships in Europe, overseeing the Company’s supply-chain and manufacturing platform, and providing business development support for several important pharmaceutical company collaborations. Prior to joining Telix, Ms. Jaume held a variety of senior product management, marketing and commercial roles at Molecubes, Siemens, CTI Molecular Imaging and IBA. Ms. Jaume’s qualifications include an M.Sc in material science from the Université Catholique de Louvain (UCL) and an MBA from the University of Chicago, Booth School of Business.

Ms. Jaume stated, “Over the past 12 months, Telix has undergone enormous activity growth in Europe, both in terms of clinical programs and academic partnerships to further build the future technology platform of the business. In a very short period, Telix has demonstrated they are a formidable player in the global nuclear medicine industry and I am pleased to be joining Chris and the team to lead the company’s European efforts.”

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinicalstage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.

Corporate Contact Investor and Media Relations Dr Christian Behrenbruch Kyahn Williamson Telix Pharmaceuticals Limited WE Buchan CEO Tel: +61 (3) 9866 4722 Email: chris@telixpharma.com Email: kwilliamson@buchanwe.com.au